Researchers evaluated automated 600-µL RoboColumns against conventional ÄKTA bench-scale chromatography and manufacturing-scale operations for purification of a bispecific antibody, focusing on whether miniaturization introduces scale-dependent biases. The study, led by an AstraZeneca scientist, qualified scale-down models against manufacturing data and then ran replicated multivariate design-of-experiments. The authors reported “excellent agreement” with manufacturing scale at target operating conditions and found negligible practical effect on resulting control strategies. While yields and product-column volumes varied between scale-down models, offsets were described as highly reproducible across process parameter ranges. For CMC teams, the relevance is operational: microscale tools could reduce material use and speed process characterization without sacrificing the analytical basis used to define controls for later stages. The work supports continued investment in miniaturized bioprocess platforms that integrate upstream experimental throughput with downstream manufacturing comparability thinking.